00:00ENV-308 is an experimental daily pill being tested for weight maintenance.
00:04It is designed for people who stop taking GLP-1 medications.
00:08The drug aims to help preserve lean muscle during weight maintenance.
00:12It also mimics LAC-V, a molecule produced during intense exercise.
00:16LAC-V may help regulate appetite and metabolic activity.
00:20The Phase I trial included 88 healthy adults.
00:23Researchers found rapid reductions in leptin levels during the trial.
00:27Animal studies also showed promising results.
00:30The drug prevented weight regain after GLP-1 treatment stopped.
00:34It also helped preserve lean muscle mass during weight loss.
00:37However, these benefits have not yet been confirmed in humans.
00:41ENV-308 also does not produce the same weight loss as GLP-1 drugs.
00:46Researchers are now planning Phase II testing to study its effects further.
00:50Early participants did not report common stomach problems like nausea or vomiting.
00:54But researchers say more testing is needed to confirm its safety.
00:58The experimental pill would not replace the benefits of exercise.
01:02Exercise remains important for heart health, sleep, circulation, and weight maintenance.
01:08ENV-308 is still in the early stages of development.
01:11It could take three to five years before possible FDA review.
01:15This video contains stock footage and content created or enhanced using AI-assisted tools.
Comments